IP Library › Granted Patent US 9,511,143
Granted Patent B2
US 9,511,143 · App. 14/344,487 · Granted Dec 6, 2016

Aqueous compositions comprising arbekacin

Inventors: Manfred Keller (Munich, DE); Yukihiro Yagi (Kanagawa, JP); Masashi Tanaka (Kanagawa, JP); Toshie Sugano (Kanagawa, JP); Kuniko Shoji (Kanagawa, JP); Nao Sano (Kanagawa, JP); Michael Hahn (Krailling, DE); Roman Egle (Munich, DE)
Assignees: Meiji Seika Pharma Co., Ltd.; PARI Pharma GmbH
A61K47/02A61K9/0078A61K9/19A61K31/7036A61K47/24C07H15/234
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,143
App. No.
14/344,487
Granted
Dec 6, 2016
Kind
B2
Abstract

The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride.

Claims (12)

1. An aqueous liquid pharmaceutical composition comprising arbekacin and chloride ions, wherein the concentration of arbekacin, calculated as free base, is at least 100 mg/ml and the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 0.9 : 1.

2. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the molar amount of sulfate ions in the composition is no greater than 200 mol-% of the molar amount of arbekacin.

3. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 3 : 1.

4. The aqueous liquid pharmaceutical composition according to claim 3 , wherein the ratio of the molar amount of chloride ions to the molar amount of arbekacin is at least 5 : 1.

5. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the composition is substantially free of sulfate ions.

6. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the composition has an osmolality of at least 350 mOsmol/kg.

7. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the composition has an osmolality of 550 to 1500 mOsmol/kg.

8. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the composition has a pH of 3 to 7.

9. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the composition has a pH of 5 to 7.

10. The aqueous liquid pharmaceutical composition according to claim 1 , wherein the arbekacin is either molecularly or colloidally dissolved.

11. A method for the treatment or prevention of a disease of the upper or lower respiratory tract, wherein the method for the treatment or prevention of the disease comprises the step of aerosolizing the aqueous liquid pharmaceutical composition of claim 1 and letting a patient inhale the aerosol thus produced.

12. Arbekacin hydrochloride in solid salt form.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2014
From: KELLER, MANFRED; YAGI, YUKIHIRO; TANAKA, MASASHI; SUGANO, TOSHIE; SHOJI, KUNIKO; SANO, NAO; HAHN, MICHAEL; EGLE, ROMAN
To: MEIJI SEIKA PHARMA CO., LTD.; PARI PHARMA GMBH
Reel/Frame 033142/0013 →
Priority Claims (1)
EP 11180927 · Sep 12, 2011 · regional
Continuity (1)
Related Publication 20140343005A1 · Nov 20, 2014